<DOC>
	<DOCNO>NCT00743184</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled study evaluate efficacy ozarelix compare placebo treatment low urinary tract symptom ( LUTS ) secondary benign prostatic hyperplasia ( BPH ) men assess International Prostate Symptom Score ( IPSS ) Week 14 .</brief_summary>
	<brief_title>Trial Safety Efficacy Ozarelix Patients With Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled study . Patients meet entry IPSS inclusion criterion Week 0 randomized enroll double-blind treatment period . Patients randomize one three treatment arm receive two 6-month course study drug administer Days 0 14 6-month course . Treatment arm include : ozarelix 30mg + 15mg , ozarelix 15mg + 15mg placebo + placebo . Safety efficacy assessment perform defined interval throughout study . At Week 52 patient study eligible receive ozarelix two additional course open-label treatment period .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Inclusion Criteria ( All must answer yes ) : 1 . Has patient give write informed consent ? 2 . Is patient least 50 year old ? 3 . Is patient diagnosed BPH clinical sign symptom BPH ≥ 6 month ? 4 . Does patient IPSS ≥ 13 ? 5 . Does patient peak urinary flow rate ( Qmax ) 415 mL/sec ( utilize 2second rule ) establish voided volume least 125 mL ? 6 . Does patient IPSS QoL score ≥ 3 ? 7 . Does patient PSA &gt; 0.8 ng/mL ? 8 . For patient PSA 4 10 ng/mL suspicion prostate cancer , patient diagnostic evaluation ( e.g. , biopsy , PSA , velocity , etc . ) reasonably exclude diagnosis prostate cancer ? 9 . Is patient willing agree use approve experimental pharmacologic BPH treatment include limited alpha blocker , 5alpha reductase inhibitor , anticholinergic preparation herbal preparation time study ? 10 . Is patient willing restrict use PDE 5 inhibitor exclusively use Viagra , one dose per week dose 5 day immediately precede schedule study visit ? 11 . Is patient willing able abide protocol ? 12 . Does patient IPSS ≥ 13 ? 13 . Does patient IPSS QoL score ≥ 3 ? 14 . Does patient postvoid residual ≤ 350cc ? Exclusion Criteria ( must answer No ) : 1 . Does patient history prostate cancer serum PSA &gt; 10 ng/mL ? 2 . Has patient prior prostate bladder surgery , pelvic surgery ( exclude hernia repair ) , pelvic radiation lower urinary tract malignancy ? 3 . Does patient prevoid total bladder volume assess ultrasound &gt; 550 mL ? 4 . Does patient post void residual urine volume ≥ 350 mL ultrasound ? 5 . Has patient take patient currently take follow : 1 . Estrogens , phytoestrogens , androgen , antiandrogens LHRH agonist within past 4 month ( e.g . testosterone gel [ Androgel ®1 % , Testim ® 1 % ] , testosterone buccal [ Striant® ] , oxymetholone [ Anadrol®50 ] , oxandrolone [ Oxandrin® ] , esterify estrogen methyltestosterone [ Estratest® ] ) , bicalutamide [ Casodex® ] , nilutamide [ Nilandron® ] , flutamide [ Eulexin® ] , leuprolide acetate [ Lupron® , Eligard® , Viadur® ] , goserelin acetate [ Zoladex® ] , 2 . 5 αreductase inhibitor within past 4 month ( e.g . finasteride [ Proscar® , Propecia® ] , dutasteride [ Avodart® ] ) , 3 . Alpha blocker anticholinergic preparation within past 6 week ( e.g . doxazosin [ Cardura® ] , terazosin [ Hytrin® ] , tamsulosin [ Flomax® ] , alfuzosin [ Uroxatrol® ] , oxybutinin [ Ditropan® ] , tolteredine [ DetrolLA® ] , amytriptyline [ Elavil® , Limbitrol® ] ) , 4 . Class 1A ( e.g . quinidine , procainamide , disopyramide ) Class III Antiarrhythmic ( e.g.sotalol [ Betapace® ] , amiodarone [ Cordarone® ] ) 6 . Does patient patient ever diagnosis acute chronic prostatitis chronic pelvic pain syndrome ? 7 . Has patient urinary tract infection instrumentation ( e.g catheterization , cystoscopy , prostate biopsy ) within past 4 week ? 8 . Does patient history urethral stricture , bladder stone , obstruct median lobe neurogenic bladder dysfunction ? 9 . Does patient microscopic hematuria great trace dipstick urine Visit 1 ? 10 . Did patient positive drug screen result ? 11 . Does patient history urinary retention ? 12 . Does patient serious medical condition ( e.g. , CHF , poorly control diabetes ( HgbA1c &gt; 9 ) , psychiatric disorder , drug alcohol abuse ) might interfere ability comply complete protocol ? 13 . Is patient 's QTc interval screen ECG &gt; 450ms , family history long QT syndrome ? 14 . Does patient anticipate plan elective surgery surgical procedure require general , spinal epidural anesthesia course doubleblind treatment portion study ( within next 12 month ) ? 15 . Has patient ever receive ozarelix , cetrorelix , tevarelix degarelix ? 16 . Has patient participate study investigational drug treatment sign symptom LUTS BPH past 12 month ? 17 . Has patient participate clinical research study study investigational drug past 90 day ?</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>BPH</keyword>
	<keyword>LUTS</keyword>
	<keyword>Lower urinary tract symptom ( LUTS )</keyword>
</DOC>